Bedrijfsoverzicht
Aethlon Medical, Inc. is a medical therapeutic company dedicated to the development of novel immunotherapeutic devices designed to treat cancer and viral infections within the United States market. The company operates within the Healthcare sector and specifically functions in the Medical Devices industry, which focuses on the creation and manufacturing of tools used for diagnosis, treatment, and monitoring of medical conditions. Currently, the firm employs a small workforce of 9 individuals, reflecting a very early-stage operational structure typical of clinical-stage biotechnology ventures. With a market capitalization of $3.40M and no reported annual revenue figures, these valuation metrics indicate that the company exists primarily as a capital-intensive research entity rather than an established revenue generator, placing it in a high-risk, high-potential niche of the healthcare market where value is derived from intellectual property and future clinical milestones rather than current sales performance.
Financiële gezondheid
The company reports a net income of $-11,522,096 over the trailing twelve-month period, while its EBITDA stands at $-7,007,023; the significant gap between these negative figures reveals a cost structure where non-operating expenses, such as interest or one-time charges, substantially widen the deficit compared to core operational profitability. Free cash flow is recorded at $-4,544,826, which indicates a substantial outflow of capital required to fund ongoing research and development activities, thereby limiting the company's immediate financial flexibility and reliance on external capital markets. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that signifies the company has not yet generated sufficient scale to cover its costs or produce a profit from its current operations. Regarding solvency, the company holds $6.96M in cash against $417,522 in debt, resulting in a debt-to-equity ratio of 6.22; despite the high leverage ratio, the substantial cash reserve suggests the balance sheet is currently conservative regarding immediate liquidity needs, as cash significantly exceeds debt obligations. The current ratio is listed at 5.68, a high figure that indicates strong short-term liquidity and the ability to meet short-term obligations with current assets, although this metric does not account for the long-term cash burn rate. Return on Equity is -208.6% and Return on Assets is -62.9%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently in the context of traditional profitability standards, which is expected for pre-revenue companies but highlights the lack of immediate capital efficiency.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is -2.21; the negative forward P/E implies that analysts or the market expects earnings to remain negative or for the company to continue operating at a loss in the near term. The price-to-book ratio is 0.31, indicating that the market values the company at a significant discount to its book value, suggesting investors are pricing in the high risk of total asset liquidation or the potential for the company to never achieve profitability. Alternative valuation metrics such as the price-to-sales ratio are reported as N/A, and the EV/EBITDA stands at 0.53, which suggests a very low enterprise value relative to earnings before interest, taxes, depreciation, and amortization, though this metric is distorted by the company's negative earnings and lack of sales data. The stock has traded between a 52-week high of $35.20 and a 52-week low of $1.36, meaning the current price sits extremely close to the bottom of this massive range, reflecting extreme volatility and a lack of recent price stability. The beta value is 1.52, which indicates that the stock price is 52% more volatile than the broader market, exposing investors to significantly higher swings in value compared to large-cap healthcare peers.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet established a historical baseline of sales to calculate meaningful growth rates. Since the company is not a dividend payer, the dividend yield and payout ratio are both N/A and 0.0% respectively, which implies that the company reinvests all available resources, however limited, into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of historical earnings growth or dividend payments, relying entirely on future clinical success to transition from a cash-burning entity to a profitable one. This profile aligns with the company's status as a clinical-stage immunotherapeutic device developer where value creation is contingent upon successful product approval and commercialization rather than current financial expansion.